monoclonal antibodies Archives

News and Trends 20 Jul 2023

Mage Biologics created to develop oral antibody therapy for ulcerative colitis

TVM Capital Life Science and specialty pharma company Tillotts Pharma are to jointly invest up to $28 million in a newly formed U.S.-based biotechnology company, Mage Biologics Inc. TVM will…

July 20, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 17 Jul 2023

Lilly boosts obesity portfolio with Versanis Bio acquisition

Eli Lilly and Company is set to acquire Versanis Bio in a deal that could be worth close to $2 billion. Versanis Bio is a private clinical-stage biopharmaceutical company focused…

July 17, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jun 2023

UCB myasthenia gravis drug given FDA approval

UCB has announced RYSTIGGO (rozanolixizumab-noli) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine…

June 27, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 1 Jun 2023

Sanofi drug reduces disease activity in relapsing MS

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a…

June 1, 2023 - 4 minutesmins - By Jim Cornall

antibody drug conjugate adc small cancer treatment

News and Trends 14 Apr 2023

TORL BioTherapeutics launches with $158M to target cancer

TORL BioTherapeutics LLC, a biopharmaceutical company focused on developing new biologics for cancer treatment, has announced its public launch and the closing of a $158 million Series B financing. TORL's…

April 14, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding…

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 17 Mar 2023

Purple Biotech sees positive results from cancer study

Purple Biotech Ltd. has released new results from exploratory analyses conducted as part of a phase 1 dose escalation study that assessed the safety and tolerability of nivolumab and CM24,…

March 17, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 14 Feb 2023

Disc Medicine raises $62.5M for hematology programs

Disc Medicine, Inc., a U.S. clinical-stage biopharma company focused on the discovery, development and commercialization of treatments for patients suffering from serious hematologic diseases, has entered into a securities purchase…

February 14, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 10 Feb 2023

Janssen reports positive topline phase 2 HDFN results

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced positive topline results from the proof-of-concept phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high…

February 10, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

BioArctic AB's partner Eisai says the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab. Lecanemab, known as LEQEMBI in the U.S., is an investigational anti-amyloid…

January 27, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Jan 2023

Dupixent gets EU nod for children with severe atopic dermatitis

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Dupixent (dupilumab), recommending expanded approval in the European Union (EU) to treat severe…

January 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

Positive Dupixent eosinophilic esophagitis phase 3 results

The New England Journal of Medicine has published results from a positive phase 3 trial showing adults and adolescents treated with Dupixent (dupilumab) 300 mg weekly experienced significant improvements in…

December 22, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 19 Dec 2022

Watch: Adrenomed tackling huge issue of sepsis

Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Its mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment…

December 19, 2022 - 1 minutemin - By Jim Cornall

News and Trends 16 Dec 2022

Astellas gastric cancer drug meets phase 3 primary endpoint

Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen…

December 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

European Commission approves Dupixent as first and only targeted prurigo nodularis medicine

The European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab…

December 15, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 15 Dec 2022

Solve Therapeutics launches to tackle cancer

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, has launched with the mission of developing novel antibody-based therapies targeting tumor-specific antigens. The company's formation reunites the former VelosBio Inc. team.…

December 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Dec 2022

Antibody discovery could lead to new therapies to tackle Strep A

Researchers at Lund University in Sweden have discovered an antibody with the potential to protect against Strep A infection, as well as a rare form of antibody binding, that leads…

December 12, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 29 Nov 2022

Touchlight receives new grant to further develop doggybone DNA vaccine platform

UK-based biotechnology company, Touchlight, has received a new grant from the Bill & Melinda Gates Foundation. The company will use the money to further its pre-clinical development of its doggybone…

November 29, 2022 - 2 minutesmins - By Liza Laws

cardiology cardiovascular disease heart attack

News and Trends 23 Nov 2022

Trial to start for new heart attack drug

A potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K. With the signing of a partnership between the University of Birmingham…

November 23, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Nov 2022

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to…

November 23, 2022 - 5 minutesmins - By Liza Laws

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with industry leaders working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering